Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 179Lung Neoplasms 60Neoplasms 24Neoplasm Metastasis 17Parkinson Disease 4, Autosomal Dominant Lewy Body 13Mesothelioma, Malignant 12Carcinoma 12Colorectal Neoplasms 10Mesothelioma 9Meningeal Carcinomatosis 8Melanoma 7Brain Neoplasms 7Adenocarcinoma of Lung 7Pancreatic Neoplasms 6Advanced Solid Tumors 5Uterine Cervical Neoplasms 4Ovarian Neoplasms 4Neoplasms by Site 4NSCLC 4Colonic Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Rectal Neoplasms 3Non-squamous Non-small Cell Lung Cancer 3Neoplasms by Histologic Type 3Lung Diseases 3Head and Neck Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma, Bronchogenic 3Adenocarcinoma 3Thoracic Neoplasms 2

Interventions

Nivolumab 11pembrolizumab 10Ipilimumab 9Cyclophosphamide 6tebentafusp 5Interleukin-2 4Blood Specimen Collection 4fludarabine phosphate 3fludarabine 3Specimen Handling 3Radiosurgery 3Melphalan 3Magnetic Resonance Spectroscopy 3relatlimab 2lenvatinib 2cemiplimab 2binimetinib 2aflibercept 2Surveys and Questionnaires 2Dacarbazine 2Crizotinib 2Carmustine 2Biopsy 2ulixertinib 1trametinib 1sargramostim 1ruxolitinib 1omipalisib 1olaparib 1lifileucel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uveal Melanoma × Pemetrexed × 1 year × Clear all
NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

iOnctura

Phase 1 Active not recruiting
210 enrolled
DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡